The only obstacle which prevents the native molecule to be used as a therapeutic agent for the treatment of diabetes is that GLP-1 is rapidly degraded within minutes by DPP-4 [34], [35], [36]. This evidence concerns the gene DPP4 and diabetes mellitus.